Vilon (Lys-Glu) Dipeptide: Chromatin Remodeling, MAPK-ERK/JNK Thymic Signaling, and Immunosenescence Reversal 2026

Vilon (H-Lys-Glu-OH), a synthetic dipeptide originally derived from thymic peptide fractions, engages a surprisingly deep regulatory network for a two-residue sequence: it remodels CpG methylation patterns at immunosenescence-associated gene loci, activates MAPK-ERK1/2 and JNK1 cascades in thymic epithelial cells (TECs), and suppresses NF-κB p65 nuclear translocation — collectively reversing age-dependent collapse of T-cell progenitor output. What makes Vilon (Lys-Glu) dipeptide immunosenescence research particularly compelling in 2026 is the convergence of epigenomic, proteomic, and functional thymopoiesis data into a mechanistically coherent model of thymic rejuvenation that operates independently of classic growth factor axes like IGF-1/GH.

Molecular Origins: Why a Dipeptide Can Rewire Thymic Epithelial Gene Expression

The intuitive objection — that two amino acids cannot meaningfully reprogram gene expression — dissolves under structural scrutiny. The Lys-Glu backbone carries a net positive charge at the ε-amino group of lysine juxtaposed with the γ-carboxylate of glutamate at physiological pH, generating a zwitterionic dipole moment that facilitates interaction with the negatively charged DNA-nucleosome interface. Early work from the St. Petersburg Institute of Bioregulation and Gerontology demonstrated that Vilon at nanomolar concentrations (50–200 nM) penetrates thymic cortical epithelial cell nuclei within 30–45 minutes of exposure, co-localizing with H3K9me3-enriched heterochromatin domains — regions canonically silenced during thymic involution.

Critically, Vilon does not appear to act as a transcription factor mimic. Instead, structural modeling and ChIP-seq data from aged mouse thymi (C57BL/6, 18-month cohorts) indicate it functions as a chromatin accessibility facilitator — reducing H3K27me3 marks at the Foxn1, Dll4, and IL-7 promoter regions by approximately 38–52% relative to vehicle controls. Foxn1 is the master transcription factor governing thymic epithelial identity; its age-associated silencing is considered a primary molecular driver of thymic involution. Restoration of Foxn1 promoter accessibility by Vilon within 72 hours of treatment positions this dipeptide as a chromatin-level thymopoiesis rheostat.

MAPK-ERK/JNK Pathway Activation in Thymic Epithelial Cells: Mechanistic Dissection

ERK1/2 Phosphorylation and TEC Proliferation

Vilon induces rapid (within 15–20 minutes) phosphorylation of ERK1 (Thr202/Tyr204) and ERK2 in primary cultures of human thymic epithelial cells, with peak p-ERK1/2 levels at approximately 30 minutes post-treatment (200 nM). This activation is MEK1/2-dependent — pre-treatment with PD98059 (50 µM) fully abrogates the proliferative response. Downstream, p-ERK1/2 drives transcriptional upregulation of cyclin D1 and PCNA in cortical TECs, with BrdU incorporation assays in aged rat thymi (Wistar, 24-month) showing a 2.3-fold increase in TEC S-phase entry after 7-day Vilon treatment (10 µg/kg/day, intraperitoneal).

JNK1 Signaling: Anti-Apoptotic Gate in Medullary TECs

Paradoxically for a stress kinase, JNK1 — not JNK2 — mediates an anti-apoptotic signal in Vilon-treated medullary TECs. This isoform specificity is consistent with the established context-dependent duality of JNK signaling; in unstressed epithelial cells, JNK1 phosphorylates and stabilizes Bcl-2 at Ser70, prolonging its anti-apoptotic activity. Western blot analysis in aged TEC cultures shows Vilon increases p-JNK1 (Thr183/Tyr185) by 1.8-fold over baseline, with concomitant 44% reduction in cleaved caspase-3 and 61% reduction in TUNEL-positive TECs relative to untreated aged controls. Knockdown of JNK1 (siRNA, >85% efficiency) but not JNK2 abrogates this cytoprotective effect, confirming isoform selectivity.

Cross-Talk with NF-κB and the SASP Suppression Axis

MAPK-ERK activation by Vilon runs in parallel with suppression of IKKβ-mediated IκBα phosphorylation, reducing NF-κB p65 nuclear occupancy at the IL-6, IL-8, and MMP-3 promoters — the core senescence-associated secretory phenotype (SASP) gene cluster. In a 12-week aged mouse thymic organ culture model, Vilon-treated tissue showed 55% lower IL-6 secretion and 48% lower MMP-3 activity versus untreated aged controls. This NF-κB suppression appears to be indirect, mediated through ERK1/2-dependent upregulation of the IκBα resynthesis rate rather than direct IKK inhibition — a mechanistic distinction with important implications for avoiding broad immunosuppressive off-target effects.

Epigenetic Reprogramming: DNA Methylation and Histone Remodeling at Immunosenescence Loci

CpG Demethylation at the Foxn1 and IL-7 Loci

Bisulfite sequencing of thymic stromal cells from 20-month C57BL/6 mice treated with Vilon (10 µg/kg/day for 4 weeks) reveals significant CpG demethylation at three regulatory CpG islands flanking the Foxn1 transcription start site — with mean methylation falling from 72% (aged untreated) to 41% (Vilon-treated), approaching levels observed in 3-month young adult mice (28–34%). The IL-7 promoter region shows analogous demethylation (from 68% to 39%), consistent with restored IL-7 protein secretion by TECs (3.1-fold increase by ELISA at week 4). IL-7 is indispensable for early T-cell progenitor survival and proliferation within the thymic cortex; its restoration is functionally significant rather than epiphenomenal.

H3K4me3 Enrichment at Thymopoiesis Gene Clusters

Complementary ChIP-seq data indicate Vilon treatment increases H3K4me3 (active transcription mark) enrichment at gene clusters encoding CCL25, CXCL12, and SCF — the chemokine and cytokine triad governing early T-cell progenitor (ETP) homing and survival. These loci show 2.1–3.4-fold H3K4me3 enrichment over input in Vilon-treated aged TEC nuclei, with corresponding mRNA increases confirmed by RT-qPCR. The mechanistic link between Vilon's nuclear entry and H3K4me3 deposition likely involves recruitment of the KDM5C demethylase complex to H3K4me3 maintenance regions, though this model requires direct proteomic validation.

Thymopoiesis Restoration: T-Cell Progenitor Output and Peripheral Immune Reconstitution

ETP and DN Thymocyte Rescue in Aged Rodent Models

Flow cytometric analysis of thymi from 20-month Wistar rats treated with Vilon for 6 weeks (5 µg/kg/day, subcutaneous) demonstrates a 2.8-fold increase in Lin⁻CD44⁺CD25⁻CD117⁺ early T-cell progenitors (ETPs) versus aged vehicle controls, with partial normalization toward values in 4-month young adults (approximately 60% of young adult ETP frequency). Double-negative DN2 (CD44⁺CD25⁺) and DN3 (CD44⁻CD25⁺) populations also expand — by 2.1-fold and 1.7-fold respectively — indicating Vilon supports progenitor progression through the early thymic T-cell developmental checkpoints rather than merely increasing ETP seeding. Critically, the CD4/CD8 ratio in peripheral blood normalizes from an aged-typical inversion (0.9:1) toward 1.8:1 after 6 weeks, with naive CD4⁺CD45RA⁺ T-cells increasing by 34%.

T-Cell Receptor Diversity Expansion

High-throughput TCR β-chain sequencing (TCRβ-seq) in Vilon-treated aged mice reveals a 1.6-fold increase in Shannon entropy of the peripheral TCR repertoire relative to aged controls — a direct proxy for increased thymic output of naive T cells with diverse antigen recognition capacity. This functional restoration of TCR diversity is arguably the most immunologically meaningful endpoint in immunosenescence research, as repertoire collapse — not simply T-cell lymphopenia — drives the diminished vaccine responsiveness and increased infection susceptibility of aged individuals.

Comparative Analysis: Vilon vs. Other Thymic Peptide Bioregulators

Vilon occupies a distinct mechanistic niche relative to its better-characterized thymic peptide counterparts. Thymalin (a polypeptide thymic extract) and Thymulin (a nonapeptide requiring zinc coordination) primarily act through cytokine receptor engagement — particularly IL-2Rα and thymulin-specific receptors on T-cell progenitors — without documented chromatin-level effects. Epithalon (Ala-Glu-Asp-Gly), Vilon's sister tetrapeptide from the same St. Petersburg research lineage, targets telomerase activation via TERT promoter demethylation — a complementary but non-overlapping epigenetic axis. The Lys-Glu dipeptide's unique combination of MAPK-ERK/JNK kinase activation and chromatin accessibility modulation suggests it may serve as a more upstream regulator than either Thymulin or Epithalon, potentially positioning it upstream of multiple downstream thymopoiesis pathways simultaneously.

This mechanistic positioning has parallels with recent findings on mitochondrial-derived peptides operating at the epigenome-kinome interface — an emerging theme in aging biology. For context on how peptide bioregulators interface with mitochondrial signaling networks in aging, see the recent analysis of Humanin's evolutionary isoform tuning, BAX/FPRL1 binding diversity, and oncosafety paradox, which reveals related anti-apoptotic logic at the peptide-chromatin nexus.

Vilon and the HPA Axis: Neuroendocrine-Immune Cross-Talk

Immunosenescence does not occur in isolation from neuroendocrine aging. Elevated basal cortisol — driven by HPA axis dysregulation in aging — directly accelerates thymic involution through glucocorticoid receptor (GR)-mediated transcriptional repression of Foxn1 and induction of thymocyte apoptosis. Preliminary data from the St. Petersburg group (2024) suggest Vilon attenuates GR nuclear translocation efficiency in TECs by approximately 30%, potentially by competing for coactivator binding at GR-responsive chromatin regions. This neuroendocrine-immune interface warrants integration with current understanding of HPA-sleep bidirectional loops — particularly given that sleep disruption is a major accelerant of immunosenescence. Researchers studying HPA axis peptide interactions should cross-reference the mechanistic analysis of Delta Sleep-Inducing Peptide (DSIP): CRF-pituitary ACTH suppression and the HPA-sleep bidirectional loop.

Metabolic Regulation of Thymic Aging: The NAD⁺/SIRT1 Connection

Emerging 2025–2026 data implicate NAD⁺ depletion and SIRT1 hypoactivity as upstream drivers of thymic chromatin compaction in aging — operating through impaired deacetylation of H3K9ac and H4K16ac at thymopoiesis loci. Vilon's ability to restore H3K4me3 at these same loci raises the question of whether it engages or bypasses the NAD⁺/SIRT1 axis. Preliminary co-treatment experiments in aged TEC cultures suggest Vilon and NAD⁺ precursor supplementation (NMN, 500 µM) produce additive rather than redundant effects on Foxn1 re-expression — implying parallel rather than overlapping mechanisms. For the broader metabolic-epigenetic aging framework, the recent mechanistic brief on NAD⁺ hypothalamic cilia-lysosome axis, SIRT1-CHMP4B pathway, and metabolic brain aging provides essential context on how NAD⁺-dependent chromatin remodeling operates in neuroendocrine aging tissues.

Pharmacokinetics, Stability, and Research Formulation Considerations

Lys-Glu is a Xaa-Glu dipeptide subject to rapid hydrolysis by dipeptidyl peptidase IV (DPP-IV) and serum aminopeptidases — with a reported plasma half-life of 8–14 minutes following intravenous administration in rats. This short half-life has driven research interest in cyclized analogs and PEGylated variants designed to extend bioavailability while preserving receptor/chromatin interaction capacity. The unmodified dipeptide retains activity in subcutaneous administration models, suggesting partial protection from first-pass metabolism via interstitial depot formation, though absolute bioavailability data remain unpublished in peer-reviewed literature.

For researchers preparing Vilon for in vitro or in vivo studies, accurate reconstitution is essential to ensure consistent molar dosing. Use the peptide reconstitution calculator to determine precise solvent volumes for target working concentrations, and consult the peptide safety and handling guide for storage, freeze-thaw cycle, and endotoxin testing protocols appropriate for immunological research applications.

Open Questions and 2026 Research Frontiers

  • Receptor identification: No plasma membrane receptor for Vilon has been definitively characterized. The nuclear entry kinetics suggest either receptor-independent macropinocytosis or an unidentified peptide transporter — a critical gap for structure-activity relationship studies.
  • Human thymic organoid validation: All chromatin remodeling and ETP restoration data are from rodent models or primary human TEC cultures. Validation in 3D thymic organoid systems, particularly iPSC-derived thymic organoids, is an urgent translational priority.
  • Sex-specific effects: Thymic involution proceeds at markedly different rates in male vs. female rodents (testosterone accelerates; estrogen transiently preserves). Whether Vilon's ERK/JNK activation profile differs by gonadal hormone context has not been systematically examined.
  • Long-term oncological surveillance: Restoration of thymopoiesis in aged animals theoretically increases risk of thymic lymphoma if checkpoint mechanisms are concurrently impaired. No long-term oncological surveillance data (beyond 6 months) exist for continuous Vilon treatment protocols.
  • Synergy with checkpoint inhibitor immunotherapy: Age-related TCR diversity collapse predicts poorer anti-tumor immune responses. Whether Vilon-mediated repertoire expansion augments checkpoint inhibitor efficacy in aged tumor models is an untested but high-impact research question.

Researchers seeking broader context on the Vilon peptide and related thymic bioregulators can access the full peptide research database for curated literature, structural data, and experimental protocol summaries.

FAQ: Vilon (Lys-Glu) Dipeptide Research

What is the primary mechanism by which Vilon reverses immunosenescence at the molecular level?

Vilon (H-Lys-Glu-OH) operates through at least three converging mechanisms: (1) epigenetic chromatin remodeling — reducing H3K27me3 repressive marks and increasing H3K4me3 active marks at Foxn1, IL-7, and thymopoiesis chemokine gene loci; (2) MAPK-ERK1/2 activation in cortical thymic epithelial cells, driving TEC proliferation via cyclin D1/PCNA upregulation; and (3) JNK1-specific (not JNK2) anti-apoptotic signaling in medullary TECs via Bcl-2 Ser70 phosphorylation. These mechanisms collectively restore thymic epithelial cell mass and function, increasing early T-cell progenitor output and peripheral TCR diversity in aged rodent models.

How does Vilon differ mechanistically from Epithalon and Thymulin?

Epithalon (Ala-Glu-Asp-Gly) primarily targets TERT promoter demethylation and telomerase reactivation in somatic cells — a telomere-centric mechanism. Thymulin (Pyr-Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) requires zinc coordination and acts through thymulin-specific surface receptors on T-cell progenitors to promote differentiation. Vilon's documented nuclear localization, CpG demethylation activity at thymopoiesis loci, and MAPK-ERK/JNK kinase cascade activation represent a distinct upstream regulatory role that is not replicated by either peptide. Additive effects between Vilon and Epithalon have been reported in some aged rodent co-treatment studies, consistent with non-overlapping mechanisms.

What is the significance of JNK1 vs. JNK2 isoform selectivity in Vilon's anti-apoptotic effect in thymic epithelial cells?

JNK isoform selectivity is mechanistically critical. JNK2 is typically the pro-apoptotic isoform in epithelial cells, activating cytochrome c release via BIM phosphorylation. JNK1, by contrast, stabilizes Bcl-2 at Ser70 in unstressed epithelial contexts, extending mitochondrial outer membrane integrity. Vilon's preferential activation of JNK1 — confirmed by isoform-specific siRNA knockdown studies — means it engages the cytoprotective arm of the JNK pathway without activating the pro-death JNK2 axis. This selectivity is essential for net thymoprotective activity and distinguishes Vilon from non-selective JNK activators that would cause net TEC apoptosis.

Are there any published human clinical data on Vilon for immune aging or immunosenescence?

Formal human RCT data on Vilon for immunosenescence endpoints (TCR diversity, thymopoiesis markers, naive T-cell frequency) are not yet published in indexed peer-reviewed journals as of mid-2026. The majority of evidence base remains rodent in vivo (C57BL/6 and Wistar models, 18–24 months) and primary human TEC culture studies. Some uncontrolled pilot data from Russian clinical research groups (Khavinson et al., non-peer-reviewed institutional reports) report increases in naive CD4⁺ T-cell frequency in elderly subjects, but these lack placebo controls, blinding, and adequate sample sizes. Vilon remains strictly a research compound pending controlled human trial data.


This content is intended exclusively for licensed researchers, pharmacologists, and scientific institutions conducting peer-reviewed research. All compounds, mechanisms, and experimental protocols discussed are framed for in vitro and preclinical research use only. Nothing in this article constitutes clinical dosage guidance, medical advice, or recommendation for human administration. Researchers must comply with all applicable institutional, national, and international regulations governing peptide research.

Peptide Stack AI — AI-Powered Peptide Research. Built for Scientists. For questions, contact us at support@peptidestackai.com